Rheumatic Heart Disease Management Market
Number of pages: 100 | Report Format: PDF | Published date: 17 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 1.10 billion |
|
Revenue forecast in 2031 |
US$ 1.66 billion |
|
Growth Rate |
CAGR of 4.7% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Drug Class, End User, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global rheumatic heart disease management market was valued at US$ 1.10 billion in 2022 and is expected to register a revenue CAGR of 4.7% to reach US$ 1.66 billion by 2031.
Market Fundamentals
The most significant consequence of rheumatic fever is rheumatic heart disease (RHD). The cause of acute rheumatic fever and rheumatic heart disease is assumed to be an immunological reaction, although the knowledge related to specific pathophysiology is lacking. Rheumatic heart disease is caused by irreversible heart valve damage caused by acute rheumatic fever, as well as rheumatic carditis including pericarditis, myocarditis, or valvulitis. Mitral valve stenosis with different degrees of regurgitation, atrial dilatation, arrhythmias, and ventricular dysfunction are all symptoms of chronic rheumatic heart disease.
The frequent symptoms of rheumatic heart disease are shortness of breath, chest discomfort, and exhaustion. However, in some cases the patient may not exhibit any symptoms until the disease has advanced to a severe stage. This medical condition can result in substantial morbidity and death, particularly if untreated. It can also cause heart failure, stroke, and other consequences, thus, negatively influencing the quality of the patient life. Depending on the severity of the condition, rheumatic heart disease therapy also include both pharmacological and surgical therapies. The major objective of rheumatic heart disease treatment is to avoid or control the disease's consequences. Antibiotics are the primary line of defense against recurrent group A streptococcal infections, which can aggravate rheumatic heart disease. Anticoagulants are also employed to prevent blood clots from developing in the heart. Surgical procedures are also commonly used to treat rheumatic heart disease. Valve repair or replacement surgery may be required to remedy rheumatic heart disease-caused valve damage.
Percutaneous balloon mitral valvuloplasty is a minimally invasive technique in which a balloon is inflated in the constricted valve to expand it and enhance blood flow. This treatment is frequently used to address mitral stenosis, a typical rheumatic heart disease consequence. Prevention is an essential component of rheumatic heart disease management.
[56756]
Market Dynamics
The global rheumatic heart disease management market is primarily driven by several factors, including increasing prevalence of rheumatic heart disease, growing awareness about the disease, and advances in medical technology. A key driver of the rheumatic heart disease management market is the rising prevalence of the disease. According to the recent study by the World Heart Federation, rheumatic heart disease affects 40 million people worldwide. It claims that each year more than 300,000 lives, accounting for nearly 2% of all deaths from cardiovascular disease, which is the number one cause of death globally. The high burden of the disease has led to an increased demand for rheumatic heart disease management products and services, driving market growth. The development of new medical technologies, such as minimally invasive surgical procedures, has made rheumatic heart disease management more effective and less invasive, leading to improved outcomes for patients. Growing awareness about rheumatic heart disease is also contributing to the growth of the market.
Moreover, governments in several countries are actively promoting rheumatic heart disease prevention and management through initiatives such as screening programs, public education campaigns, and funding for rheumatic heart disease research. Furthermore, the availability of government initiatives and funding for rheumatic heart disease management is expected to drive market growth. Additionally, limited management procedures with poor diagnostics techniques, stringent regulatory policies, and lack of awareness among the people can further complicate the market situation, hence, hampering the overall growth of the global market.
Market Ecosystem
The global rheumatic heart disease management market has been analyzed from three perspectives: Drug Class, End User, and Region
Rheumatic Heart Disease Management Market by Drug Class
[54644]
Based on the drug class, the global rheumatic heart disease management market can be further segmented into anti-inflammatory, anti-coagulant, antibiotics, and others.
Antibiotics registered for the largest share in term of sales in global rheumatic heart disease management market in 2022, and is expected to retain its dominance during the projected timeframe. Since antibiotics are an essential part of the management and prevention of rheumatic heart disease. Rheumatic fever, which is the primary cause of rheumatic heart disease, is caused by a bacterial infection, usually group A streptococcus. Antibiotics are used to treat the infection and prevent the development of rheumatic heart disease. Antibiotics are also used in the management of rheumatic heart disease to prevent the recurrence of rheumatic fever, which can cause further damage to the heart valves. Patients with rheumatic heart disease are often prescribed prophylactic antibiotics to prevent the recurrence of rheumatic fever and reduce the risk of valve damage.
In addition, antibiotic therapy is used in the management of infective endocarditis, a serious complication of rheumatic heart disease. Infective endocarditis is an infection of the heart valves or inner lining of the heart, which can cause damage to the valves and lead to heart failure. Antibiotics are used to treat the infection and prevent further valve damage. In addition, the use of antibiotics in rheumatic heart disease management has been supported by various international organizations, including the American Heart Association (AHA). These organizations have recommended the use of antibiotics in the prevention and management of rheumatic heart disease, which has driven the demand for antibiotics in the market.
Similarly, anti-inflammatory drugs segment is estimated to depict steady growth during the forecast period from 2023 to 2031. As inflammation plays a significant role in the development and progression of rheumatic heart disease. Anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, can help reduce the inflammation and prevent further damage to the heart valves. They are commonly used to manage the symptoms of RHD, such as joint pain and swelling, and to prevent the progression of the disease. Other medications may also be used in the management of RHD, such as antibiotics to treat the underlying streptococcal infection and medications to manage heart failure or other complications that may arise.
Rheumatic Heart Disease Management Market by End User
Based on the end user, the global rheumatic heart disease management market can be further segmented into hospitals, ambulatory surgical centers, and others.
Hospitals segment accounts for the largest revenue share in the global market. Hospitals typically have specialized departments, such as cardiology, and are highly equipped with the necessary expertise and facilities to diagnose and manage rheumatic heart disease effectively. These departments are staffed with trained physicians and healthcare professionals who have experience in managing the disease. Hospitals typically also has the access to advanced technology and equipment, such as echocardiography machines, which are necessary for accurate diagnosis and monitoring of rheumatic heart disease. This type of medical setting also offers comprehensive care for rheumatic heart disease patients, including medical management, surgical interventions, and rehabilitation services. This type of care is necessary for the effective management of rheumatic heart disease, which can be a complex and chronic disease. Hospitals are often easily accessible for patients, especially in urban areas where there are multiple hospitals. This accessibility can be important for patients who require urgent medical attention for rheumatic heart disease-related complications.
Rheumatic Heart Disease Management Market by Region
Based on the region, the global rheumatic heart disease management market can be further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America led the rheumatic heart disease management market in terms of revenue, and this trend is likely to continue during the forecast period. The growing urbanization in this region is a primary driver of the coronary stent market. Constant development in this region leads to an unhealthy lifestyle, which causes obesity, and therefore an increase in the incidence of heart ailments, expecting market development. Moreover, the fast use of sophisticated technology in various stent materials propels the market forward. Whereas Europe holds the market's second highest revenue share. Increased acceptance and implementation of sophisticated technology, as well as improved healthcare infrastructure, are all contributing to the growth of the rheumatic heart disease management market in this region.
Asia Pacific area is expected to increase significantly throughout the forecast period. Some of the key drivers driving market expansion in Asia Pacific include the growing older population, fast increasing prevalence of cardiovascular diseases, increased acceptability and knowledge of ablation cardiovascular disease therapy, and an expanding number of ablation product manufacturers. Developing markets such as China, India, Brazil, and Mexico have also gained traction among firms involved in the research, production, and marketing of cardiac ablation devices.
Competitive Landscape
These are global healthcare company that undertakes the development, manufacture and marketing of pharmaceuticals, vaccines, and consumer health related products. It continues to harness its leading market position, pharmaceuticals segment and sturdy research activities to deliver strong operational performance. Expansion initiatives, promising pipeline products and product approvals could provide growth opportunities to the company. However, intense competition, product liability claims coupled with government regulations could affect its profitability.
The prominent players operating in the global rheumatic heart disease management market are:
Antibiotics segment dominates the global rheumatic heart disease management market with the largest revenue share.
The global rheumatic heart disease management market will grow at a CAGR of 4.7% during the projected period.
Asia Pacific is projected to be the fastest-growing region in the global rheumatic heart disease management market.
Pfizer Inc, Novartis AG, Abbott Laboratories Inc., and other notable players are some of the prominent market players.
The estimated market size of the rheumatic heart disease management market is US$ 1.66 billion in 2031.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst